Tocotrienols: Inflammation and cancer

Annals of the New York Academy of Sciences

Volumn 1229, Issue 1, 2011, Pages 18-22

  Nesaretnam, Kalanithi ^a   Meganathan, Puvaneswari ^a  

^a MALAYSIAN PALM OIL BOARD   (Malaysia)

Author keywords

Anti inflammation; Cancer; COX 2; Inflammation; NF B; STAT3; Tocotrienols

Indexed keywords

ALPHA TOCOPHEROL; ALPHA TOCOTRIENOL; CELECOXIB; CYCLIN D1; CYCLOOXYGENASE 2; DOCETAXEL; ERLOTINIB; GEMCITABINE; GENE PRODUCT; GLUCOCORTICOID; I KAPPA B; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 6; NATURAL PRODUCT; STAT3 PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CARCINOGENESIS; CELL PROLIFERATION; DOWN REGULATION; DRUG POTENTIATION; GENE TARGETING; HUMAN; INFLAMMATION; METASTASIS; NEOPLASM; NONHUMAN; PANCREAS CANCER; TUMOR GROWTH; UNSPECIFIED SIDE EFFECT;

EID: 79960772295     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2011.06088.x     Document Type: Article

References (26)

1. Aggarwal, B.B. & P. Gehlot 2009. Inflammation and cancer: how friendly is the relationship for cancer patients Curr. Opin. Pharmacol. 9: 351-369.
2. American Cancer Society (2011). Cancer Facts & Figures 2010. Accessed 27 Mar 2011.
3. Aggarwal, B.B., S. Shishodia, S.K. Sandur, M.K. Pandey & G. Sethi 2006. Inflammation and cancer: how hot is the link Biochem. Pharmacol. 72: 1605-1621.
4. Shafiq, N., S. Malhotra, P. Pandhi & R. Nada 2005. Comparative gastrointestinal toxicity of selective cyclooxygenase (COX-2) inhibitors. Indian J. Exp. Biol. 43: 614-619.
5. Nesaretnam, K. 2008. Multitargeted therapy of cancer by tocotrienols. Cancer Lett. 269: 388-395.
6. Sen, C.K., S. Khanna & S. Roy 2006. Tocotrienols: vitamin E beyond tocopherols. Life Sci. 78: 2088-2098.
7. Nesaretnam K., N. Guthrie, A.F. Chambers & K.K. Carroll 1992. Effect of tocotrienols on the growth of a human breast cancer cell line in culture. Lipids 30: 1139-1145.
8. Nesaretnam, K., P.A. Gomez, K.R. Selvaduray & G. Abdul Razak 2007. Tocotrienol levels in adipose tissue of benign and malignant breast lumps in patients in Malaysia. Asia Pac. J. Clin. Nutr. 16: 498-504.
9. Sen, R. & D. Baltimore 1986. Inducibility of kappa immunoglobulin enhancer-binding protein Nf-kappa B by a posttranslational mechanism. Cell 47: 921-928.
10. Ahn, K.S., G. Sethi, K. Krishnan & B.B. Aggarwal 2007. Gamma-tocotrienol inhibits nuclear factor-kappaB signaling pathway through inhibition of receptor-interacting protein and TAK1 leading to suppression of antiapoptotic gene products and potentiation of apoptosis. J. Biol. Chem. 282: 809-820.
11. Tak, P.P & G.S. Firestein 2001. NF-kB: a key role in inflammatory diseases. J. Clin. Invest. 107: 7-11.
12. Wu, S.J., P.L. Liu & L.T. Ng 2008. Tocotrienol-rich fraction of palm oil exhibits anti-inflammatory property by suppressing the expression of inflammatory mediators in human monocytic cells. Mol. Nutr. Food Res. 52: 921-929.
13. Kunnumakkara, A.B., B. Sung & J. Ravindran 2010. Gamma-tocotrienol inhibits pancreatic tumors and sensitizes them to gemcitabine treatment by modulating the inflammatory microenvironment. Cancer Res. 70: 8695-8705.
14. Hussein, D. & H. Mo 2009. d-Delta-tocotrienol-mediated suppression of the proliferation of human PANC-1, MIA PaCa-2, and BxPC-3 pancreatic carcinoma cells. Pancreas 38: e124-e136.
15. Yap WN., N. Zaiden, Y.L. Tan, et al 2010. Id1, inhibitor of differentiation, is a key protein mediating anti-tumor responses of gamma-tocotrienol in breast cancer cells. Cancer Lett. 291: 187-199.
16. Kannappan, R., V.R. Yadav & B.B. Aggarwal 2010. Gamma-tocotrienol but not gamma-tocopherol blocks STAT3 cell signaling pathway through induction of protein-tyrosine phosphatase SHP-1 and sensitizes tumor cells to chemotherapeutic agents. J. Biol. Chem. 285: 33520-33528.
17. Benekli, M., X. Zheng, K.A. Donahue, et al 2002. Constitutive activity of signal transducer and activator of transcription 3 protein in acute myeloid leukemia blasts is associated with short disease-free survival. Blood 99: 252-257.
18. Normanno, N., C. Bianco, A. De Luca, et al 2003. Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment. Endocr. Relat. Cancer 10: 1-21.
19. Olayioye, M.A., R.M. Neve, H.A. Lane & N.E. Hynes 2000. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J. 19: 3159-3167.
20. Bachawal, S.V., V.B. Wali & P.W. Sylvester 2010. Combined γ-tocotrienol and erlotinib/gefitinib treatment suppresses STAT and Akt signaling in murine mammary tumor cells. Anticancer Res. 30: 429-438.
21. Mukherjee, D., S.E. Nissen & E.J. Topol 2001. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 286: 954-959.
22. Tomisato, W., S. Tsutsumi, T. Hoshino, et al 2004. Role of direct cytotoxicity effects of NSAIDs in the induction of gastric lesions. Biochem. Pharmacol. 67: 575-585.
23. Shirode, A.B. & P.W. Sylvester 2010. Synergistic anticancer effects of combined gamma-tocotrienol and celecoxib treatment are associated with suppression in Akt and NFkB signaling. Biomed. Pharmacother. 64: 327-332.
24. Shibata A, K. Nakagawa P. Sookwong, et al 2008. Tocotrienol inhibits secretion of angiogenic factors from human colorectal adenocarcinoma cells by suppressing hypoxia-inducible factor-1alpha. J. Nutr. 138: 2136-2142.
25. Mun-Li, Y., S.R. Abdul Hafid, C. Hwee-Ming, & K. Nesaretnam 2009. Toocotrienols suppress proinflammatory markers and cyclooxygenase-2 expression in RAW264.7 macrophages. Lipids 44: 787-797.
26. Ndlovu, M.N., C.V. Lint, K.V. Wesemael, et al 2009. Hyperactivated NF-kB and AP-1 transcription factors promote highly accessible chromatin and constitutive transcription across the Interleukin-6 gene promoter in metastatic breast cancer cells. Mol. Cell. Biol. 29(20): 5488-5504.